SMITHKLINE BEECHAM WILL MARKET GENERIC TAGAMET TO MANAGED CARE GROUPS; LEDERLE SHIPMENTS TO WHOLESALERS, RETAIL PHARMACIES SET TO BEGIN MAY 16
SmithKline Beecham will manufacture a generic version of Tagamet (cimetidine) under the label of its Penn Labs subsidiary and market the product to hospitals and managed care organizations, the company said May 10. SB will manufacture generic cimetidine under the Tagamet NDA. The generic version will be yellow to distinguish it from the pale green color of the branded product, the company said.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth